KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Depreciation & Amortization (CF) (2023 - 2025)

Biocryst Pharmaceuticals' Depreciation & Amortization (CF) history spans 9 years, with the latest figure at $394000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 27.51% year-over-year to $394000.0; the TTM value through Dec 2025 reached $1.4 million, up 11.48%, while the annual FY2025 figure was $1.4 million, 11.48% up from the prior year.
  • Depreciation & Amortization (CF) reached $394000.0 in Q4 2025 per BCRX's latest filing, up from $335000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $423000.0 in Q4 2023 to a low of $306000.0 in Q1 2024.
  • Average Depreciation & Amortization (CF) over 3 years is $357500.0, with a median of $333000.0 recorded in 2025.
  • Peak YoY movement for Depreciation & Amortization (CF): fell 26.95% in 2024, then grew 27.51% in 2025.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $423000.0 in 2023, then dropped by 26.95% to $309000.0 in 2024, then grew by 27.51% to $394000.0 in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Depreciation & Amortization (CF) are $394000.0 (Q4 2025), $335000.0 (Q3 2025), and $329000.0 (Q2 2025).